Full Breakdown
Supreme Court Review Sought After 5th Circuit Blocks Mail-Order Mifepristone
5/3/2026, 8:30:52 AM
5th Circuit Blocks Mail Distribution of Mifepristone
On May 1, 2026 5th Circuit Court of Appeals ordered that mifepristone be dispensed only in person at clinics, overturning FDA’s 2023 rule that allowed mail and telehealth delivery. The injunction halts nationwide channel for medication abortions.
Regulatory Background
The FDA’s 2023 rule removed in-person requirement for mifepristone, a change made in 2021 after Roe v. Wade was overturned. In 2024 Supreme Court dismissed a challenge, and Louisiana AG Liz Murrill sued, arguing rule defeats state’s abortion ban.
Key Players and Data
The case pits Danco Laboratories, maker of Mifeprex, and GenBioPro against Louisiana and FDA. Judge Kyle Duncan wrote Fifth Circuit opinion. Mifepristone, approved in 2000 and used with misoprostol, accounts for over half of U.S. abortions; one-quarter are obtained via telemedicine.
Implications
The ruling could limit an FDA-approved medication, restricting access for patients in restrictive states and those relying on remote care. It arrives weeks before 2026 midterms, where abortion policy is key issue, and raises a legal question about overturning longstanding FDA drug regulations.
Official Statements & Responses
The FDA and DOJ declined comment; Louisiana AG Liz Murrill called the decision a “victory for life.” Danco’s petition to Supreme Court argued order “injects confusion and upheaval into medical decisions” and sought a stay. Fifth Circuit Judge Duncan said Louisiana is likely to succeed because FDA rule ignored safety risks like sepsis and hemorrhage, and noted agency has not set a timeline for safety review.
Criticism & Opposition
Planned Parenthood and National Women’s Law Center called the ruling a step backward that endangers patients. Anti-abortion advocates praised it as restoring state-ban intent, while leaders criticized President Trump for not acting.
Conflicting Reports & Gaps
The FDA has not set a timeline for its safety review, leaving the 2023 rule’s future uncertain. Providers claim telehealth has prevented a post-Roe decline in abortions, but no data confirm it.
Verbatim Quotes
- “We're now going to see, I think in a way we haven't before, what the nation will look like when abortion bans are actually in effect,” — Mary Ziegler, professor, UC Davis School of Law
- “The regulation creates an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law,” — Judge Kyle Duncan, Fifth Circuit
- “We will do everything in our power to continue providing care to people in all 50 states,” — Dr. Angel Foster, The Massachusetts Medication Abortion Project
- “deeply out of step with both the public and fact-based science.” — Fatima Goss Graves, president and CEO, National Women’s Law Center
What's Next
The Supreme Court will hear Danco’s petition in the coming weeks, determining whether mail-order distribution resumes while the appeal proceeds.
